After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
You'll never make money just following the Federal Reserve, Cramer said.
Cubist Pharmaceuticals on Tuesday committed up to $1.6 billion to acquire two makers of next-generation antibiotics in a bid to expand aggressively its acute care product portfolio.
Jim Cramer looks at the implications of the latest biotech deal, Cubist acquiring Trius, and the implications for the biotech sector.
U.S. stock futures suggest a flat to slightly higher start for Wall Street; Cubist Pharmaceuticals makes two acquisitions; MasterCard and Comcast highlight the earnings calendar.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.